NICE 20 Oct 2026
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment
TA1202
20 Oct 2026
Read →
These trials are currently recruiting participants in the UK. Always speak to your GP or specialist before contacting a trial team.
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose…
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer…
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate…
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide…
Background and Study Aims: Melanoma is the most dangerous form of skin cancer, and early detection is crucial for improving patient outcomes.…
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and…
Your patient insight is valuable. Take a short survey and help researchers improve treatments for Cancer.
Living with Cancer? Your experience can help others. Share what you've learned.
Thousands of UK patients are managing Cancer. Connect, share experiences, and support each other.
The latest pipeline drugs, clinical breakthroughs, and regulatory approvals from the FDA, EMA and NICE for Cancer patients.
TA1202
TA1197
📋 Information sourced from clinical trial registries, FDA, EMA and published research
View all research →No podcasts available yet for Cancer
Sign up for updates below to be notified when we release a free patient podcast for this area.